Macera Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Latest Deal Type
-
Series A1
- Investors
-
8
Macera Therapeutics General Information
Description
Manufacturer of macrophage immunotherapy drugs designed to treat gastric cancer, liver cancer, prostate cancer, and other solid tumors and autoimmune diseases. The company's drugs have integrated and non-integrated molecular editing and manipulation systems, iPSC-derived immune cell differentiation systems, ligand-receptor and other information flow recognition and conduction technology platforms, enabling doctors to kill tumor cells and regulate autoimmune cell cloning.
Contact Information
Corporate Office
- Room 745, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
- Number 3-1 Xinjinhu Road, Jiangbei New District
- Nanjing, Jiangsu 210031
- China
Corporate Office
- Room 745, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
- Number 3-1 Xinjinhu Road, Jiangbei New District
- Nanjing, Jiangsu 210031
- China
Macera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A1) | 17-May-2026 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 23-Jun-2025 | Completed | Generating Revenue | |||
| 2. Seed Round | 03-Jan-2023 | Completed | Startup | |||
| 1. Seed Round | 07-Dec-2022 | Completed | Startup |
Macera Therapeutics Patents
Macera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026223521-A1 | Cytokine combination for preventing and/or treating fibrosis | Pending | 22-Apr-2025 | ||
| WO-2026114326-A1 | Intracellular signaling domain of chimeric antigen receptor and use thereof | Pending | 28-Nov-2024 | ||
| WO-2026016944-A1 | Adenovirus vector and use thereof | Pending | 15-Jul-2024 | ||
| WO-2024093147-A1 | Antibody specifically binding to v5 exon of cd44, and use thereof | Inactive | 31-Oct-2022 | C07K16/2884 |
Macera Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dingxin Capital | Venture Capital | Minority | ||
| Fan Zhuo Capital | Corporate Venture Capital | Minority | ||
| Zijin Hi-Tech Venture Capital | Venture Capital | Minority | ||
| Nanjing Innovation Capital Group | Venture Capital | Minority | ||
| CDH Investments | PE/Buyout | Minority |
Macera Therapeutics FAQs
-
When was Macera Therapeutics founded?
Macera Therapeutics was founded in 2022.
-
Where is Macera Therapeutics headquartered?
Macera Therapeutics is headquartered in Nanjing, China.
-
What industry is Macera Therapeutics in?
Macera Therapeutics’s primary industry is Drug Discovery.
-
Is Macera Therapeutics a private or public company?
Macera Therapeutics is a Private company.
-
What is Macera Therapeutics’s current revenue?
The current revenue for Macera Therapeutics is .
-
Who are Macera Therapeutics’s investors?
Dingxin Capital, Fan Zhuo Capital, Zijin Hi-Tech Venture Capital, Nanjing Innovation Capital Group, and CDH Investments are 5 of 8 investors who have invested in Macera Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process